Maxim Group Initiates Coverage on BioHarvest Sciences (NASDAQ:BHST)

Maxim Group started coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a research report released on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $12.00 price target on the stock.

Separately, HC Wainwright initiated coverage on shares of BioHarvest Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $14.00 target price on the stock.

BioHarvest Sciences Stock Down 0.8 %

BHST traded down $0.05 during midday trading on Wednesday, reaching $6.15. 241 shares of the company’s stock were exchanged, compared to its average volume of 3,549. The stock has a market cap of $101.01 million and a price-to-earnings ratio of -4.92. BioHarvest Sciences has a one year low of $6.15 and a one year high of $7.70.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.